Argos Therapeutics, Inc. (NASDAQ:ARGS)’s share price gapped up before the market opened on Thursday . The stock had previously closed at $0.24, but opened at $0.23. Argos Therapeutics shares last traded at $0.21, with a volume of 3,744,373 shares.

Separately, Zacks Investment Research downgraded Argos Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, August 14th. One research analyst has rated the stock with a sell rating and three have issued a hold rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $3.23.

The firm’s 50-day moving average is $0.23 and its 200-day moving average is $0.51. The stock’s market cap is $11.43 million.

Argos Therapeutics (NASDAQ:ARGS) last announced its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.21) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.22) by $0.01. The business had revenue of $0.07 million for the quarter, compared to analyst estimates of $0.10 million. Argos Therapeutics had a negative return on equity of 1,532.49% and a negative net margin of 12,391.15%. Analysts expect that Argos Therapeutics, Inc. will post ($1.14) EPS for the current year.

COPYRIGHT VIOLATION WARNING: This article was originally posted by Daily Political and is owned by of Daily Political. If you are viewing this article on another publication, it was copied illegally and republished in violation of United States and international copyright legislation. The original version of this article can be read at

About Argos Therapeutics

Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.